Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin

Experimental Hematology

Volumn 34, Issue 6, 2006, Pages 802-808

  Steiner, David ^a   Brunicki, Noga ^a   Bachar Lustig, Esther ^a   Taylor, Patricia A ^b   Blazar, Bruce R ^b   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; RAPAMYCIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; SIROLIMUS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 33646703806     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.02.017     Document Type: Article

References (43)

1. Davison G.M., Novitzky N., Kline A., et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 69 (2000) 1341-1347
2. Mencacci A., Perruccio K., Bacci A., et al. Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. Blood 97 (2001) 1483-1490
3. Pan L., Delmonte Jr. J., Jalonen C.K., and Ferrara J.L. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86 (1995) 4422-4429
4. Small T.N., Papadopoulos E.B., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 93 (1999) 467-480
5. Volpi I., Perruccio K., Tosti A., et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 97 (2001) 2514-2521
6. Weinberg K., Blazar B.R., Wagner J.E., et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 97 (2001) 1458-1466
7. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
8. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
9. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
10. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
11. Einsele H., Schafer H.J., Hebart H., et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 121 (2003) 411-418
12. Bishop M.R., Hou J.W., Wilson W.H., et al. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant 9 (2003) 162-169
13. Levine J.E., Uberti J.P., Ayash L., et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 9 (2003) 189-197
14. Aversa F., Tabilio A., Terenzi A., et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84 (1994) 3948-3955
15. Lapidot T., Terenzi A., Singer T.S., Salomon O., and Reisner Y. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 73 (1989) 2025-2032
16. Bachar-Lustig E., Rachamim N., Li H.W., Lan F., and Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1 (1995) 1268-1273
17. Reisner Y., and Martelli M.F. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 16 (1995) 437-440
18. Uharek L., Gassmann W., Glass B., et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 79 (1992) 1612-1621
19. Uchida N., Tsukamoto A., He D., Friera A.M., Scollay R., and Weissman I.L. High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. J Clin Invest 101 (1998) 961-966
20. Aversa F., Tabilio A., Velardi A., et al. Transplantation of high-risk acute leukemia with T-cell-depleted stem cells from related donor with one fully mismatched HLA haplotype. N Engl J Med 339 (1998) 1186-1193
21. Bachar-Lustig E., Li H.W., Gur H., Krauthgamer R., Marcus H., and Reisner Y. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by sca-1(+)Lin(-) bone marrow progenitor cells: synergism with non- alloreactive (Host × Donor)F(1) T cells. [In Process Citation]. Blood 94 (1999) 3212-3221
22. Reisner Y., and Martelli M.F. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Immunol Today 20 (1999) 343-347
23. Rachamim N., Gan J., Segall H., et al. Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 65 (1998) 1386-1393
24. Gur H., Krauthgamer R., Berrebi A., et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood 99 (2002) 4174-4181
25. + progenitor cells: evidence for a deletion-based mechanism mediated by TNF-{alpha}. Blood 105 (2005) 2585-2593
26. Taylor P.A., Lees C.J., and Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99 (2002) 3493-3499
27. Hoffmann P., Ermann J., Edinger M., Fathman C.G., and Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196 (2002) 389-399
28. Cohen J.L., Trenado A., Vasey D., Klatzmann D., and Salomon B.L. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 196 (2002) 401-406
29. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 112 (2003) 1688-1696
30. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 104 (2004) 1565-1573
31. + immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 8 (2002) 525-535
32. + T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 9 (2003) 243-256
33. + T lymphocytes. Blood 103 (2004) 4216-4221
34. Hanash A.M., and Levy R.B. Donor CD4(+)CD25(+) T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 105 (2005) 1828-1836
35. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104 (2004) 3804-3812
36. Bachar-Lustig E., Reich-Zeliger S., and Reisner Y. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 102 (2003) 1943-1950
37. Di Joseph J.F., Fluhler E., Armstrong J., Sharr M., and Sehgal S.N. Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat. Transplantation 62 (1996) 1109-1112
38. Cutler C., and Antin J.H. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 471-476
39. Johnston L.J., Brown J., Shizuru J.A., et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 47-55
40. Li Y., Zheng X.X., Li X.C., Zand M.S., and Strom T.B. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 66 (1998) 1387-1388
41. Taylor P.A., Lees C.J., Wilson J.M., et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 100 (2002) 3400-3407
42. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., and Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21 (2004) 589-601
43. +FoxP3+ regulatory T cells. Blood 105 (2005) 4743-4748